<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02118337</url>
  </required_header>
  <id_info>
    <org_study_id>D6020C00001</org_study_id>
    <nct_id>NCT02118337</nct_id>
  </id_info>
  <brief_title>A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies</brief_title>
  <official_title>A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination with
      Durvalumab versus Nivolumab Monotherapy in Subjects with Select Advanced Malignancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label, Phase 1/2 study to evaluate the safety, tolerability, PK,
      immunogenicity, and antitumor activity of MEDI0680 in combination with durvalumab or
      nivolumab monotherapy in adult immunotherapy-na√Øve subjects with selected advanced
      malignancies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 19, 2014</start_date>
  <completion_date type="Actual">March 17, 2020</completion_date>
  <primary_completion_date type="Actual">March 17, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Escalation: Number of subjects with adverse events</measure>
    <time_frame>From first dose of study drugs until 90 days after the last dose of study drugs</time_frame>
    <description>Assessed by number of subjects with AEs and SAEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Expansion: Antitumor activity</measure>
    <time_frame>From first dose of study drug through study completion</time_frame>
    <description>Determination of antitumor activity based on investigator assessed response using RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation: Antitumor activity of MEDI0680 in combination with MEDI4736 in subjects with select advanced malignancies</measure>
    <time_frame>From first dose of study drugs through study completion</time_frame>
    <description>Determination of antitumor activity based on investigator assessed response using RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Expansion: Safety of MEDI0680 Monotherapy and in combination with MEDI4736</measure>
    <time_frame>From first dose through 90 days after last dose of study drugs</time_frame>
    <description>To be assessed by number of subjects with AEs and SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Expansion: Antitumor activity of MEDI0680 monotherapy and in combination with MEDI4736</measure>
    <time_frame>From the time of first dose through study completion</time_frame>
    <description>Determination of antitumor activity based on blinded independent central review assessed response using RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Both Phases: Pharmacokinetics of MEDI0680 monotherapy and in combination with MEDI4736 and MEDI4736 in combination with MEDI0680</measure>
    <time_frame>From first dose until 12 months after the last dose</time_frame>
    <description>Pharmacokinetics as measured by drug concentration in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Both Phases: Immunogenicity of MEDI0680 and MEDI4736</measure>
    <time_frame>From first dose of study drugs until 12 months after last dose of study drugs</time_frame>
    <description>Immunogenicity as measured by presence of detectable ADAs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD-L1 as a predictive biomarker</measure>
    <time_frame>From first dose of study drug through study completion</time_frame>
    <description>PD-L1 expression on the tumor membrane and tumor-infiltrating immune cells within the tumor microenvironment</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Select Advanced Malignancies</condition>
  <condition>Kidney Cancer</condition>
  <condition>Clear Cell Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>0.1 mg/kg MEDI0680 Q2W; 3 mg/kg durvalumab Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI0680 and Durvalumab in combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivolumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nivolumab monotherapy at the selected dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI0680 and Durvalumab combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.1 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI0680 and Durvalumab in combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.5 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI0680 and Durvalumab in combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI0680 and Durvalumab in combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI0680 and Durvalumab in combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 mg/kg MEDI0680 Q2W; 750 mg durvalumab Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI0680 and Durvalumab in combination</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI0680</intervention_name>
    <description>anti-PD-1</description>
    <arm_group_label>0.1 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W</arm_group_label>
    <arm_group_label>0.1 mg/kg MEDI0680 Q2W; 3 mg/kg durvalumab Q2W</arm_group_label>
    <arm_group_label>0.5 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W</arm_group_label>
    <arm_group_label>10 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W</arm_group_label>
    <arm_group_label>2.5 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W</arm_group_label>
    <arm_group_label>20 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W</arm_group_label>
    <arm_group_label>20 mg/kg MEDI0680 Q2W; 750 mg durvalumab Q2W</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>anti-PD-L1</description>
    <arm_group_label>0.1 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W</arm_group_label>
    <arm_group_label>0.1 mg/kg MEDI0680 Q2W; 3 mg/kg durvalumab Q2W</arm_group_label>
    <arm_group_label>0.5 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W</arm_group_label>
    <arm_group_label>10 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W</arm_group_label>
    <arm_group_label>2.5 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W</arm_group_label>
    <arm_group_label>20 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>anti PD-1</description>
    <arm_group_label>Nivolumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be 18 years or older

          -  Eastern Cooperative Oncology Group performance status of 0-1

          -  Adequate organ function

          -  At least 1 prior line of therapy

        Exclusion Criteria:

          -  Concurrent enrollment in another clinical study, unless in follow-up period or it is
             an observational study

          -  Concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer
             treatment

          -  Prior treatment with immunotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Chow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Omid Hamid, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Angeles Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jhanelle Gray, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moffitt Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rachel Sanborn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Providence Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamad Salkeni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mary Babb Randolph Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Monika Joshi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State Hershey Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Alter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>John Theurer Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raid Aljumaily, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peggy Charles Stephenson Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jason Chesney, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernando Quevedo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Voss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johanna Bendell</last_name>
    <role>Principal Investigator</role>
    <affiliation>SCRI Development Innovations, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth Henry</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loyola Univ. Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lionel Lewis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brian Rini</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Van Veldhuizen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Menorah Medical Center tour</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>East Bentleigh</city>
        <zip>3165</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankston</city>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris Cedex 15</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Korea, Republic of</country>
  </removed_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 11, 2014</study_first_submitted>
  <study_first_submitted_qc>April 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2014</study_first_posted>
  <last_update_submitted>April 10, 2020</last_update_submitted>
  <last_update_submitted_qc>April 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>select advanced malignancies,</keyword>
  <keyword>kidney cancer,</keyword>
  <keyword>clear cell renal cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

